Deciphera Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 66 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-09: Reporting owner Sherman Matthew L; Form 4; Security Stock Option (Right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-01: Reporting owner Taylor Michael Douglas; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-11-16: Reporting owner Sherman Matthew L; Form 4; Security Stock Option (Right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-11-04: Reporting owner Taylor Michael Douglas; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-09 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −207 147,096 owned after | $34.43 exercise price | 2020-12-11 | |
| 2020-12-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −19,000 45,354 owned after | $1.89 exercise price | 2020-12-03 | |
| 2020-11-16 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,697 147,303 owned after | $34.43 exercise price | 2020-11-18 | |
| 2020-11-04 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 64,354 owned after | $1.89 exercise price | 2020-11-06 | |
| 2020-11-02 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,315 79,354 owned after | $1.89 exercise price | 2020-11-04 | |
| 2020-10-09 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,541 0 owned after | $1.89 exercise price | 2020-10-13 | |
| 2020-10-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −104,635 0 owned after | $1.89 exercise price | 2020-10-05 | |
| 2020-10-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,365 102,669 owned after | $1.89 exercise price | 2020-10-05 | |
| 2020-09-14 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 47,008 owned after | $1.89 exercise price | 2020-09-16 | |
| 2020-09-10 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 50,008 owned after | $1.89 exercise price | 2020-09-10 | |
| 2020-09-08 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,000 53,008 owned after | $1.89 exercise price | 2020-09-10 | |
| 2020-08-20 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −187 396,813 owned after | $25.40 exercise price | 2020-08-24 | |
| 2020-08-10 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,029 0 owned after | $1.89 exercise price | 2020-08-12 | |
| 2020-07-22 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −130,000 9,029 owned after | $1.89 exercise price | 2020-07-24 | |
| 2020-07-20 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −188 397,000 owned after | $25.40 exercise price | 2020-07-22 | |
| 2020-07-15 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +723 723 owned after | $34.58 | 2020-07-17 | |
| 2020-07-15 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +723 723 owned after | $34.58 | 2020-07-17 | |
| 2020-07-15 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +723 723 owned after | $34.58 | 2020-07-17 | |
| 2020-07-15 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +723 723 owned after | $34.58 | 2020-07-17 | |
| 2020-07-15 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +723 723 owned after | $34.58 | 2020-07-17 | |
| 2020-07-15 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +723 723 owned after | $34.58 | 2020-07-17 | |
| 2020-07-09 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,324 0 owned after | $1.89 exercise price | 2020-07-13 | |
| 2020-07-09 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,217 23,541 owned after | $1.89 exercise price | 2020-07-13 | |
| 2020-07-06 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −27,544 104,635 owned after | $1.89 exercise price | 2020-07-06 | |
| 2020-07-02 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −48,245 132,179 owned after | $1.89 exercise price | 2020-07-06 | |
| 2020-07-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −49,211 180,424 owned after | $1.89 exercise price | 2020-07-06 | |
| 2020-06-18 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −187 397,188 owned after | $25.40 exercise price | 2020-06-19 | |
| 2020-06-10 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Martin John Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-10 | Benz Edward J. JR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $56.46 exercise price | 2020-06-12 | |
| 2020-06-05 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,635 0 owned after | $25.73 exercise price | 2020-06-05 | |
| 2020-06-03 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,365 5,635 owned after | $25.73 exercise price | 2020-06-05 | |
| 2020-05-28 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −188 397,375 owned after | $25.40 exercise price | 2020-06-01 | |
| 2020-05-11 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,000 59,008 owned after | $1.89 exercise price | 2020-05-13 | |
| 2020-04-28 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 229,635 owned after | $1.89 exercise price | 2020-04-30 | |
| 2020-04-21 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −187 397,563 owned after | $25.40 exercise price | 2020-04-23 | |
| 2020-04-17 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,892 254,635 owned after | $1.89 exercise price | 2020-04-21 | |
| 2020-04-14 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,108 278,527 owned after | $1.89 exercise price | 2020-04-16 | |
| 2020-04-09 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −23,542 16,324 owned after | $1.89 exercise price | 2020-04-13 | |
| 2020-04-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −75,000 279,635 owned after | $1.89 exercise price | 2020-04-03 | |
| 2020-02-18 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −42,190 42,190 owned after | $54.87 exercise price | 2020-02-20 | |
| 2020-02-18 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −10,520 10,520 owned after | $54.87 exercise price | 2020-02-20 | |
| 2020-02-18 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −42,190 42,190 owned after | $54.87 exercise price | 2020-02-20 | |
| 2020-02-18 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +180,000 180,000 owned after | $54.87 exercise price | 2020-02-20 | |
| 2020-01-24 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 10,233 owned after | $3.95 exercise price | 2020-01-28 | |
| 2020-01-22 | Martin Daniel C. Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | C Conversion of derivative security | −26,999 63,001 owned after | $36.10 exercise price | 2020-01-24 | |
| 2020-01-16 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4/A | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,106 4,944 owned after | $3.95 exercise price | 2020-01-22 | |
| 2020-01-16 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,106 29,444 owned after | $3.95 exercise price | 2020-01-21 | |
| 2020-01-16 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −56,800 94,817 owned after | $6.13 exercise price | 2020-01-21 | |
| 2020-01-16 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,011 150,344 owned after | $3.95 exercise price | 2020-01-17 | |
| 2020-01-15 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,023 153,355 owned after | $3.95 exercise price | 2020-01-17 | |
| 2020-01-08 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,281 165,378 owned after | $3.95 exercise price | 2020-01-09 | |
| 2020-01-07 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,650 177,659 owned after | $3.95 exercise price | 2020-01-09 | |
| 2020-01-03 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −31,422 354,635 owned after | $1.89 exercise price | 2020-01-06 | |
| 2020-01-03 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,359 71,008 owned after | $1.89 exercise price | 2020-01-06 | |
| 2020-01-03 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,989 39,866 owned after | $1.89 exercise price | 2020-01-06 | |
| 2020-01-02 | Morl Christopher John Officer (Chief Business Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,137 179,309 owned after | $3.95 exercise price | 2020-01-06 | |
| 2020-01-02 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −93,578 386,057 owned after | $1.89 exercise price | 2020-01-06 | |
| 2020-01-02 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,641 75,367 owned after | $1.89 exercise price | 2020-01-06 | |
| 2020-01-02 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,553 47,855 owned after | $1.89 exercise price | 2020-01-06 |